MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) today announced that it has entered into an agreement with DoctorDirectory.com Inc., the Company’s promotion partner for MOXATAG (amoxicillin extended-release) Tablets, 775 mg, to expand its previously announced IncreaseRx® promotion program. The expanded IncreaseRx® promotion program for MOXATAG will incorporate physicians previously detailed by the Company’s field sales force. IncreaseRx® performs as a virtual contract sales organization, providing health care professionals with access to electronic sampling, electronic learning and online educational tools. The expanded IncreaseRx® promotion program for MOXATAG will utilize web-based educational and promotional tactics to reach prescribers with targeted MOXATAG sales and marketing messages.
“We look forward to providing a promotional boost for MOXATAG through IncreaseRx® and providing increased access to MOXATAG samples and information to physicians nationwide.”
Dave Becker, acting president and chief executive officer of MiddleBrook said, “Under this expanded IncreaseRx® program, physicians who previously received MOXATAG samples and information from MiddleBrook field sales representatives will be able to request samples and receive important product information electronically. We will be able to reach more than 150,000 physicians across the nation through the expanded IncreaseRx® program for MOXATAG.”
Jay Grobowsky, president and CEO of DoctorDirectory, said, “We look forward to providing a promotional boost for MOXATAG through IncreaseRx® and providing increased access to MOXATAG samples and information to physicians nationwide.”
Gene editing restores hearing and balance in adult mice with DFNA41 deafness